<DOC>
	<DOCNO>NCT02530905</DOCNO>
	<brief_summary>This first-in-human dose-titration open-label extension study ass safety , tolerability , pharmacokinetics SRP-4045 advanced-stage Duchenne muscular dystrophy ( DMD ) patient deletion amenable exon 45 skipping .</brief_summary>
	<brief_title>Dose-Titration Open-label Extension Study SRP-4045 Advanced Stage Duchenne Muscular Dystrophy ( DMD ) Patients</brief_title>
	<detailed_description>This randomize , placebo-controlled dose-titration study ass safety , tolerability , pharmacokinetics 4 dose level SRP-4045 genotypically confirm advanced-stage DMD patient deletion amenable exon 45 skipping . After completion dose-titration portion study SRP-4045 determine safe , patient evaluate open-label SRP-4045 duration study . Safety , include adverse event monitoring , routine laboratory assessment , cardiac testing monitor duration dose-titration open-label portion study . Clinical efficacy assess regularly schedule study visit via quality life questionnaires test pulmonary upper extremity function duration dose-titration open-label portion trial .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Genotypically confirm DMD ( amenable exon 45 skip ) . Stable cardiac pulmonary function . Limited ambulation . On stable dose oral corticosteroid least 24 week OR receive corticosteroid least 24 week . Current previous treatment experimental agent SMT C1100 ( BMN195 ) PRO045 . Other experimental treatment past 12 week . If cardiac medication , must stable dose past 12 week . Major surgery within past 3 month . Other inclusion/exclusion criterion apply .</criteria>
	<gender>Male</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Duchenne muscular dystrophy</keyword>
	<keyword>Exon Skipping</keyword>
</DOC>